Shares of Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX) saw an uptick in trading volume on Thursday . 468,247 shares were traded during mid-day trading, an increase of 43% from the previous session’s volume of 327,331 shares.The stock last traded at $6.75 and had previously closed at $6.32.

A number of research firms have recently weighed in on FOMX. Guggenheim restated a “buy” rating and issued a $10.00 price target on shares of Foamix Pharmaceuticals in a report on Tuesday, May 10th. Zacks Investment Research cut shares of Foamix Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Wednesday, May 4th.

The firm’s 50 day moving average price is $6.54 and its 200-day moving average price is $6.58. The stock’s market cap is $210.61 million.

Foamix Pharmaceuticals (NASDAQ:FOMX) last issued its quarterly earnings data on Tuesday, May 10th. The specialty pharmaceutical company reported ($0.15) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.23) by $0.08. On average, equities analysts predict that Foamix Pharmaceuticals Ltd. will post ($0.89) earnings per share for the current fiscal year.

An institutional investor recently raised its position in Foamix Pharmaceuticals stock. Tekla Capital Management LLC increased its stake in shares of Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX) by 6.3% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 652,145 shares of the specialty pharmaceutical company’s stock after buying an additional 38,568 shares during the period. Tekla Capital Management LLC owned about 2.13% of Foamix Pharmaceuticals worth $5,289,000 at the end of the most recent quarter.

Foamix Pharmaceuticals Ltd. is a clinical-stage specialty pharmaceutical company. The Company is focused on developing and commercializing its minocycline foam for the treatment of acne, rosacea, impetigo and other skin conditions. The Company operates in the segment of development and commercialization of foam-based formulations.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.